BioSpace News Archive

Vertex Announces Publication in The New England Journal of Medicine of Phase 3 Results for TRIKAFTA ® (elexacaftor/tezacaftor/ivacaftor and ivacaftor) in People With Cystic Fibrosis

Ironwood Pharmaceuticals Announces FDA Approval of Revised LINZESS ® (linaclotide) Label based on clinical safety data that has been generated thus far in pediatric studies.

Avalo Therapeutics, Inc. (Nasdaq: AVTX), a leading clinical-stage precision medicine company that discovers, develops, and commercializes targeted therapeutics for patients with significant unmet clinical need in immunology, immuno-oncology, and rare genetic diseases announced today that it has launched its new corporate name Avalo Therapeutics, Inc.

Edesa Biotech, Inc. today provided an update on a Phase 2/3 clinical study evaluating the company’s monoclonal antibody candidate as a single-dose therapy for hospitalized COVID-19 patients.

Adagene Inc. today reported financial results for the six months ended June 30, 2021, and provided corporate updates.

Heat Biologics,Inc. (“Heat”)(NASDAQ:HTBX), a clinical-stage biopharmaceutical company focused on developing first-in-class therapies to modulate the immune system, today announced the launch of its wholly-owned subsidiary, Skunkworx Bio, Inc. (“Skunkworx”), focused on the development of a drug discovery paradigm to enable rapid drug development.

Pardes Biosciences, Inc., a clinical-stage biopharmaceutical company today announced the initiation of a Phase 1 clinical trial, evaluating the company’s lead candidate, PBI-0451 which is being developed as a potential oral direct-acting antiviral to treat and prevent infections with SARS-CoV-2, the virus that causes COVID-19.

MEI Pharma, Inc. today announced that the Company will release its 2021 fiscal year end financial results after the close of the U.S. financial markets on September 2, 2021.

INOVIO today announced that it has received regulatory authorization from Brazil’s ANVISA to initiate the global Phase 3 segment of its Phase 2/3 trial, INNOVATE

Metagenomi today announced the addition of Willard H. Dere, M.D., to the company’s board of directors.